ArticleJournal of cellular biochemistry2025
RING-Box E3 Ligase Target N-Terminal Lysine 55 to Regulate Turnover of Sp7 Protein.
Article in Journal of cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Specificity protein 7 (Sp7) is essential for osteoblast differentiation and bone formation. In humans, Sp7 gene mutations are associated with skeletal abnormalities, including osteogenesis imperfecta. Ubiquitylation regulates the cellular levels of Sp7 protein. However, the role of the largest class of E3 ubiquitin ligases in the turnover of Sp7 protein remains unknown. Here, we report for the first time that both catalytic subunits of multi-subunit RING-box E3 ligase, Rbx1 and Rbx2, are expressed in the skeletal tissues and during osteoblast differentiation. In situ immunofluorescence and biochemical fractionation revealed that in osteoblasts, Rbx1 and Rbx2 E3 ligase reside in both the cell cytoplasm and nucleus. The coimmunoprecipitation experiment in primary osteoblasts showed that endogenous Rbx1 and Rbx2 E3 ligase form a molecular complex with the Sp7 protein. Both Rbx1 and Rbx2 enzymes target Sp7 protein for ubiquitination. Sp7 protein is degraded by Rbx1 and Rbx2 enzymes in a dose-dependent manner in both osseous and non-osseous cells. Chemical inhibition established the requirement of Rbx1 and Rbx2-mediated ubiquitination and degradation of Sp7 protein by the proteasomal pathway. In-silico analysis identified three evolutionarily conserved lysines, K-55, K-227, and K-229, in the Sp7 protein as potential targets for ubiquitination. A panel of Sp7 deletion and point mutants was generated that established the critical requirement of lysine-55 for Rbx1 and Rbx2-mediated ubiquitination and degradation. Deleting the Rbx2 gene in osteoprogenitors led to a significant accumulation of Sp7 protein, enhanced expression of osteoblast marker genes, and accelerated matrix mineralization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.